Lincoln Pharmaceuticals is currently trading at Rs. 119.90, up by 4.90 points or 4.26% from its previous closing of Rs. 115.00 on the BSE.
The scrip opened at Rs. 116.00 and has touched a high and low of Rs. 122.00 and Rs. 116.00 respectively. So far 257107 shares were traded on the counter.
The BSE group 'B ' stock of face value Rs. 10 has touched a 52 week high of Rs. 127.70 on 10-Aug-2015 and a 52 week low of Rs. 38.50 on 14-Aug-2014.
Last one week high and low of the scrip stood at Rs. 127.70 and Rs. 113.40 respectively. The current market cap of the company is Rs. 192.79 crore.
The promoters holding in the company stood at 36.54% while Institutions and Non-Institutions held 0.01% and 63.45% respectively.
Lincoln Pharmaceuticals has successfully launched a cough syrup ‘NAMCOLD-DX’, which contains Dextromethorphan Polistirex. This is an Extended Release, unique product of Novel Technology. ‘NAMCOLD-DX’ is designed for all age group of patient above 4 years. The product is time tested and many trials have been done and it is approved by Drug Controller General of India (DCGI).
Normal cough syrups are effective up to 3-4 hours, so in 24 hours the patient has to take the syrup 4 to 5 times. But, this innovative product ‘NAMCOLD-DX’ is extended release, so the drug releases periodically and therefore the patient has to take only 2 doses during 24 hours.
Lincoln Pharmaceuticals is a company is based at Ahmedabad and engaged in Manufacturing and Export of Pharmaceuticals formulations under various Therapeutic product group, plant duly complied with WHO-GMP guidelines. The Company is exporting more than 45 countries along with Domestic market in more than 20 states in India.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1804.50 |
Dr. Reddys Lab | 1201.45 |
Cipla | 1551.30 |
Lupin | 2104.90 |
Zydus Lifesciences | 879.85 |
View more.. |